Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4609337 | 1.00 | MAPK14 (0.56) | MAPK14HPGDNPC1RAB9ALCK | |
| SCHEMBL5000635 | 0.97 | MAPK14 (0.57) | MAPK14HPGDLCKSRCKDR | |
| SCHEMBL5000629 | 0.97 | MAPK14 (0.57) | MAPK14HPGDLCKSRCKDR | |
| SCHEMBL4608277 | 0.94 | MAPK14 (0.56) | MAPK14NPC1RAB9ALCKSRC | |
| SCHEMBL4608275 | 0.94 | MAPK14 (0.56) | MAPK14NPC1RAB9ALCKSRC | |
| SCHEMBL4609947 | 0.94 | MAPK14 (0.59) | MAPK14HPGDRAB9ALCKSRC | |
| SCHEMBL4609953 | 0.94 | MAPK14 (0.59) | MAPK14HPGDRAB9ALCKSRC | |
| SCHEMBL4609524 | 0.93 | MAPK14 (0.55) | MAPK14NPC1RAB9A | |
| SCHEMBL4609531 | 0.93 | MAPK14 (0.55) | MAPK14NPC1RAB9A | |
| SCHEMBL4609364 | 0.93 | MAPK14 (0.56) | MAPK14HPGDNPC1RAB9ALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449474-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1747204-B1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | PROCTER & GAMBLE (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | MAPK14 2674/4885HPGD 612/4885NPC1 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.